The global precision medicine market size was USD 87.70 billion in 2023, calculated at USD 102.17 billion in 2024 and is expected to reach around USD 470.53 billion by 2034, expanding at a CAGR of 16.5% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Precision Medicine Market, by Technology Type, 2024-2034
7.1.1. Bioinformatics
7.1.1.1. Market Revenue and Forecast (2021-2034)
7.1.2. Big Data Analytics
7.1.2.1. Market Revenue and Forecast (2021-2034)
7.1.3. Drug Discovery
7.1.3.1. Market Revenue and Forecast (2021-2034)
7.1.4. Gene Sequencing
7.1.4.1. Market Revenue and Forecast (2021-2034)
7.1.5. Companion Diagnostics
7.1.5.1. Market Revenue and Forecast (2021-2034)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2021-2034)
8.1. Precision Medicine Market, by Application, 2024-2034
8.1.1. CNS
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Immunology
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Oncology
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Respiratory
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Precision Medicine Market, by End-Use, 2024-2034
9.1.1. Diagnostic Companies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Healthcare IT companies
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1. Biocrates Life Sciences
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Tepnel Pharma Services
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Qiagen
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Quest Diagnostics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Menarini Silicon Biosystems
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. NanoString Technologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eagle Genomics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Pfizer
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Intomics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Roche
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Teva Pharmaceutical
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample